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Abstract 
Background and aims: In smoking treatment trials comparing varenicline with transdermal 
nicotine replacement therapy (NRT), stratified by nicotine metabolite (3-
hydroxycotinine/cotinine) ratio (NMR), the relative benefit of varenicline is greater among 
normal rather than slow metabolisers. This study tested if the relative effectiveness of 
varenicline and NRT is associated with NMR status in a natural treatment setting. A secondary 
aim was to test if this relationship is moderated by behavioural support. 
Design: Prospective observational multi-centre study with 4-week and 52-week follow-up. 
Setting: Nine English Stop Smoking Services (SSS) 
Participants: Data came from 1,556 smokers (aged ≥16 years) attending SSS between March-
2012 and March-2013. 
Interventions: Participants received pharmacotherapy together with behavioural support. 
Measurements: The primary outcome was carbon-monoxide verified continuous abstinence 
at both follow-up times. Main explanatory variables were 1) NMR status (slow [NMR<0.31, 
N=454] vs. normal [NMR≥0.31, N=1,109] metabolisers); 2) Pharmacotherapy (varenicline vs. 
NRT) and 3) Behavioural support (individual vs. group-based treatment). Analyses adjusted 
for baseline sociodemographic, SSS, mental/physical health and smoking characteristics. 
Findings: Of participants, 44.2% (95% confidence interval (CI) 41.7-46.6%) and 8.0% 
(95%CI 6.8-9.5%) were continuously abstinent at 4-weeks and 52-weeks. Varenicline was 
more effective than NRT at 4-weeks (p<0.001) but only marginally so at 52-weeks (p=0.061). 
There was no or inclusive evidence that NMR status moderated relative efficacy of varenicline 
and NRT at 4-week (p=0.60, Bayes Factor (BF)=0.25) or 52-week follow-ups (p=0.74, 
BF=0.73). However, this relationship was moderated by behavioural support (p=0.012): the 
This article is protected by copyright. All rights reserved. 
relative benefit of varenicline over NRT at 52-week follow-up was greater in slow, not normal, 
metabolisers receiving group rather than individual support (p=0.012). 
Conclusions: In a real-world setting, the nicotine metabolite ratio status of treatment-seeking 
smokers does not appear to contribute substantially to the differential effectiveness of 
varenicline and nicotine replacement therapy in Stop Smoking Services, when both 
pharmacotherapy and behavioural support are self-selected. 
Keywords: Nicotine metabolism, smoking, smoking cessation, stop smoking services, nicotine 
replacement therapy, varenicline, pharmacogenomics  
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Introduction 
Despite the existence of effective behavioural and pharmacological smoking cessation 
interventions, most treatment-seeking smokers will still fail even with additional support.(1-7) 
Given our increasing understanding of the molecular genetics of smoking and evidence of 
substantial heritability for tobacco addiction,(8, 9) one option to improve cessation rates is to 
prescribe pharmacological treatment on the basis of genetically-informed biomarkers.(10, 11) 
The rationale is that the same genetic factors which predispose an individual to nicotine 
addiction may also moderate the response to pharmacotherapy.(12) One such candidate 
biomarker is the nicotine metabolite ratio (NMR), calculated as the quotient of two major 
metabolites of nicotine (3’hydroxycotinine (3HC) and cotinine), which functions as a 
phenotypic surrogate of nicotine clearance.(13) 
The liver enzyme CYP2A6, part of the cytochrome P450 enzyme system, is largely responsible 
for the metabolism of nicotine into cotinine,(14) and exclusively responsible for cotinine’s 
metabolism into 3’hydroxycotinine.(15) The encoding gene CYP2A6 is highly polymorphic 
and has been associated with nicotine dependence and smoking behaviour.(16, 17) However, 
as a phenotypic marker, NMR has an advantage over genotypic markers by incorporating 
genetic, environmental and demographic influences on nicotine metabolism.(18, 19) It can also 
be measured easily and non-invasively from saliva and urine as well as blood.(20) Both NMR 
and categorised NMR (into slow vs normal/fast metabolisers) have been shown to be stable 
over time in ad libitum (21, 22) and treatment-seeking smokers,(23) and independent of 
smoking patterns and time since last cigarette given the comparatively long half-lives of 
cotinine and 3HC.(13, 21) The NMR appears suitable for one-time assessments, correlates well 
with clearance of nicotine that is orally or intravenously administered (13, 24) and is not 
affected by time of sampling.(21, 25) Although NMR varies somewhat with sex,(26) race,(27), 
age(28) and body-mass index,(22) it is relatively consistent across different socio-demographic 
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and health characteristics, with such factors accounting for less than 8-9% in variance of 
NMR.(19, 29, 30) However NMR can be influenced by both environmental inducers and 
inhibitors, some of which can be transitory.(19) 
NMR is related to smoking behaviour in a number of ways. Smokers with a higher NMR, who 
therefore metabolise nicotine more quickly, also tend to be heavier smokers.(31) In addition, 
faster metabolisers appear to smoke cigarettes more intensely, resulting in higher exposure to 
tobacco-related carcinogens.(32) However, the association of NMR with nicotine dependence 
and withdrawal symptoms is less clear-cut, with some but not all studies finding an association 
of greater dependence and more severe withdrawal symptoms among faster metabolisers.(20, 
31) Similarly, data on the association of NMR with smoking cessation outcomes are mixed. 
On the one hand, studies of pharmacological treatments have shown that slow metabolisers 
tend to have lower relapse rates than normal/fast metabolisers when treated with nicotine 
patch,(33, 34) with placebo(35) and irrespective of treatment provided,(36) whereas other 
studies have found an opposite pattern, with lower relapse rates among faster metabolisers 
using nicotine replacement therapy (with metabolism defined by genotype)(37) or when not 
using any treatment (with metabolism defined by NMR).(38) Others still find no difference in 
the effect of NMR on treatment with NRT but higher overall abstinence rates among slow 
metabolisers.(39) Reflecting this uncertainty in the literature, a recent Cochrane review was 
inconclusive with regards to superior efficacy of specific pharmacological treatment as a 
function of NMR.(40) 
The most rigorous assessment of the potential role of NMR for personalising pharmacotherapy 
for smoking cessation comes from a recent placebo-controlled clinical trial which prospectively 
randomized to treatment arm (varenicline or NRT patch) by NMR stratification.(41) Clinical 
trials directly comparing varenicline with NRT have shown that varenicline is generally more 
effective than NRT.(42) In contrast, this study found a significant NMR by treatment 
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interaction, suggesting that varenicline was relatively more effective than transdermal NRT 
only for normal/fast (6-months abstinence rates: 22% vs. 13.6%) but not slow metabolisers 
(19.1% vs. 21.6%). The implication is that in future normal/fast metabolisers should 
preferentially be prescribed varenicline and slow metabolisers transdermal NRT. However, 
given conflicting evidence to date and a call for replication and validation of NMR studies in 
different contexts,(43) extension of these findings to other populations (treatment-seeking 
smokers), different operationalisations of NMR and geographic locations is now required. This 
is particularly important since there are well-known differences in the treatment provision and 
participant characteristics for clinical trials as compared with general population studies,(44) 
and consequent failures to replicate trial findings, e.g. for smoking cessation treatments, (45) 
based on real-world data. We have previously shown that the choice of pharmacotherapy in 
real-world settings (stop smoking services in England, SSS) is not influenced by NMR status, 
suggesting there is scope to optimise treatment allocation.(30) However, in this context it is 
also be important to consider other non-pharmacological treatment factors as the uptake of 
behavioural support was shown to differ as a function of NMR status, with normal metabolisers 
being less likely to choose group over individual support than slow metabolisers.(30) The 
importance of this needs to be explored further. 
 
In a large sample of treatment seekers in the UK, the present study therefore aimed to: 
1) test whether NMR status (slow vs. normal) moderates the short- and long-term 
effectiveness of NRT compared with varenicline for smoking cessation in real-world 
settings 
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2) assess whether results are consistent across different operationalisations of NMR (as a 
continuous measure or based on quartiles) or when restricting pharmacotherapy to 
varenicline and transdermal nicotine patch alone 
3) test whether this relationship is moderated by the type of behavioural treatment 
(individual or group support) received  
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Methods 
Design 
This is a prospective observational study (‘Evaluating Long-term Outcomes of NHS Stop 
Smoking Services’) or ‘ELONS’ study carried out in nine SSS across three regions of England 
(North, South and Midlands). Participants were recruited into the study at their first visit, where 
stage they provided saliva samples to determine NMR status, and were followed up via the SSS 
up until 4 weeks post their quit date to determine short-term continuous abstinence. Participants 
confirmed to be abstinent at 4-week follow-up were re-contacted by the research team at 52 
weeks post-quit to determine long-term continuous abstinence. 
Participants and Procedure 
The ELONS study recruited and consented 3,044 participants, who were not pregnant and aged 
16 or above, who accessed nine SSS in England between March 2012 and March 2013 and set 
a firm quit date. 
For the purpose of this analysis, participants who elected to not receive pharmacotherapy, only 
bupropion or who chose combination therapy of NRT with varenicline or bupropion were 
excluded. Full details on ELONS methodology can be found elsewhere.(46) Of ELONS 
participants, 61.6% (N=1,875) agreed to provide saliva samples prior to start of treatment (of 
which 44 samples were not useable and five lost in the post; see (47) for details) and 51.1% 
(N=1,556) had complete baseline data and fulfilled inclusion and exclusion criteria, and thus 
constitute the analytic sample. In addition to providing saliva samples, participants also 
completed questionnaires to assess sociodemographic, smoking, health-related, and treatment 
characteristics prior to start of treatment.  
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Measures 
Outcome variables 
Short- and long-term continuous abstinence 
Continuous abstinence were assessed at both 4-week and 52-week follow-up post target quit 
date.(46) As per standard SSS criteria, abstinence at 4-week follow-up was defined as complete 
abstinence from smoking in the past two weeks, verified by an expired air-carbon monoxide 
(CO) reading below 10ppm, conducted at the SSS. As this study was only interested in 
determining verified prolonged abstinence, only those participants who were defined as 
abstinent at 4-week follow-up were further followed up at 52 weeks. Smoking abstinence was 
again verified by CO reading, conducted at the home of participants by the market research 
company TNS BMRB. Following recommended practice, participants lost to follow up were 
considered to be still smoking.(48) 
Explanatory variables 
Nicotine Metabolite Ratio 
Saliva samples were collected with Sarstedt Salivettes® and posted to University College 
London where they were stored in -20°C freezers before being shipped to the University of 
Toronto or ABS laboratories for analysis. As earlier interlaboratory studies have shown 
comparable results among different these laboratories,(49, 50) which was also the case in the 
current study (see (30) for details), analyses from both laboratories were pooled. As described 
previously,(30) established LC-MS/MS methodology with a 1 ng/mL limit of quantification 
(LOQ),(25, 50) was used to determine cotinine (COT) and trans-3’-hydroxycotinine (3HC) 
levels in saliva samples to calculate the NMR ratio (3HC/COT). Examination for analytical 
shift and reliability (conducted on 5% of samples) showed NMR results to be highly reliable 
(R2=0.984) with no association between change in NMR and time between analyses 
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(R2=0.004). Given that NMR may be unstable for occasional and light smokers,(51) samples 
with cotinine values below the standard cut-off for smoking (10 ng/ml) were excluded. In cases 
where COT values were above 10 ng/ml but 3HC was below the limit of quantification (LOQ), 
the 3HC value was replaced by LOQ divided by the square root of two to compute the 
NMR.(52) Based on population data from the previous prospectively NMR randomized clinical 
trial, (41) participants in the analytic sample were classified into normal (NMR≥0.31; N=1,105; 
71.0%) or slow (NMR<0.3; N=451; 29.0%) metaboliser (see Table 1). Further information on 
socio-demographic differences by NMR status has been published elsewhere.(46)  
Pharmacotherapy and behavioural support characteristics 
In this observational study, following consultation, participants freely chose their treatment 
that was recorded by SSS practitioners. Pharmacotherapy was dichotomised into varenicline or 
NRT product use (single or combined NRT). As indicated above, participants with combination 
non-NRT/NRT treatment, bupropion or no pharmacotherapy were excluded from the analysis. 
The type of behavioural support chosen was also recorded as individual (one-to-one; non-group 
drop-in) vs. group-based (open/rolling groups; closed groups) support. Further information on 
socio-demographic differences by treatment characteristics has been published elsewhere.(46) 
Covariates 
Sociodemographic characteristics 
Standard sociodemographics (age, sex, socioeconomic status (SES), ethnicity, marital status) 
were recorded by SSS staff at baseline. SES was measured with the National Statistics Socio-
economic Classification (NSSEC)(53) was used as a measure of SES grouped into higher vs. 
lower SES, using the NSSEC coding ABC1/C2DE (managerial occupations/manual and 
unemployed). Due to a relatively small number of participants with an ethnic minority 
background, ethnicity was split into White British and other. 
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Stop Smoking Service and smoking characteristics  
As local funding rules and policies are likely to affect treatment choice and success rates,(54) 
SSS location was recorded, divided into North, Midlands and South regions of England. At 
baseline, nicotine dependence was measured with the Heaviness of Smoking Index (HSI)(55), 
classifying participants as having high dependence (HSI score 4-6) or low dependence (HSI 
score 0-3).(56) Determination to quit was assessed on a one-item 4-point Likert scale (ranging 
from ‘not at all determined’ to ‘extremely determined’) and whether participants had attempted 
to quit in the previous 12 months was also recorded (yes/no). 
Health-related characteristics 
Participants were asked to provide information about any medical conditions and those with at 
least one condition were coded as having poorer physical health compared with those without. 
Participants also completed the World Health Organisation (WHO)-5 wellbeing index,(57) a 
tool used in primary care to determine psychological wellbeing using five questions scored 
from 0-5 with higher scores indicating better quality of life.  Scores were summated and 
converted into a percent of the maximum score (25) with scores ≤50% indicating low subjective 
wellbeing.(58) 
Analyses 
In univariate analyses, group differences between the analytic and excluded sample in 
sociodemographic, smoking, health-related, NMR and treatment characteristics and smoking 
outcomes were assessed using chi-square/t-tests for categorical/continuous variables, 
respectively. Multi-variable log-binomial generalised linear models were used to provide risk 
ratios (RR). Analyses tested the independent relationships between smoking outcomes at 4-
week and 12-month follow-up and predictors, including a pharmacotherapy choice (NRT vs. 
varenicline) by NMR status (slow vs normal NMR) interaction term to determine whether 
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treatment effectiveness varied as a function of nicotine metabolism as well as their respective 
main effects, adjusting for covariates in Table 1. Age was transformed using the standard 
deviation of the variable as the scaling factor as it did not meet linearity assumptions.(59) Due 
to insufficient numbers, SSS location was not modelled as a random effect but included as a 
covariate in analysis. In sensitivity analyses, NMR status was also defined based on quartiles 
to classify slow (1st quartile) vs fast (4th quartile) metabolisers and NMR was entered as a 
continuous variable. Bayes factors (BF) were also calculated for the primary analysis using 
standard cut-offs to confirm findings and determine whether results can be interpreted as 
evidence to support the null-hypothesis (BF <1/3), the alternative hypothesis (BF >3) or 
whether data were inclusive (BF 1/3< and <3). This was based on detecting an effect equivalent 
to the clinical trial data (41), using standard methodology with a half-normal distribution and 
mean difference parameter estimates to represent the alternative hypothesis (60). Furthermore, 
given that previous clinical work had compared only the relative effectiveness of NRT patch 
vs varenicline among slow and normal metabolisers,(41) the sample was restricted to users of 
these specific pharmacotherapies, and as the uptake of group vs. individual support has been 
shown to differ as a function of NMR status,(30) a higher order interaction term (behavioural 
support x NMR status x pharmacotherapy) in addition to lower order interaction terms and 
main effects was included in the main model to assess robustness of findings.  
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Results 
 
As shown in Table 1, the analytic sample (N=1,556) was somewhat younger, less likely to be 
female, white, to be extremely determined to quit or from the North of England than the 
excluded sample. They were also more likely to use group support. However, NMR status did 
not differ between those participants in the analytic and excluded samples who had provided 
saliva (Table 1). At 4-week follow-up, 44.2% (95% confidence interval (CI) 41.7-46.6%) of 
participants were verified as continuously abstinent; this rate dropped to 8.0% (95%CI 6.8-
9.5%) at the 12-month follow-up. Figure 1 shows the raw abstinence rates broken down by 
type of pharmacotherapy used and NMR status (supplementary Figure S1 presents adjusted 
data). 
 
1) Does NMR status moderate the short- and long-term effectiveness of nicotine compared with 
non-nicotine pharmacotherapy in SSS? 
The effect of pharmacotherapy on outcomes did not appear to be moderated by NMR status. 
This was confirmed in adjusted analysis. There was no interaction of NMR status by 
pharmacotherapy choice on either 4-week or 52-week follow-ups when controlling for all other 
variables (see Table 2). Bayes factors indicated that for the 4-week follow-up there was no 
effect (BF=0.25) but that for the 52-week follow-up data were inconclusive (BF=0.73). Given 
the lack of a support for the alternative hypothesis, the interaction term was therefore removed 
for the analyses below. Greater abstinence rates at 4-week and 52-week follow-up were 
independently associated with lower dependence and being married or cohabiting. Higher 
socio-economic status and use of varenicline were also associated with greater abstinence rates 
at 4-week follow-up but only marginally so at 52-week follow-up (Table 2). In addition, older 
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age, greater determination to quit, using group support and attending SSS in the North or 
Midlands region of England were associated with greater abstinence rates at 4-week follow-
up, only. 
 
2) Are results consistent across different operationalisations of NMR or when restricting 
pharmacotherapy to varenicline and transdermal nicotine patch alone? 
Further sensitivity analyses were conducted to assess the robustness of findings. Characterising 
participants into slow vs fast metabolisers based on quartiles or using NMR as a continuous 
variable did not affect the observed associations, or lack thereof. Similarly, restricting the 
sample to NRT patch and varenicline users only did not alter results materially (see 
Supplementary Tables S1-S3). 
3) Is the relationship between smoking cessation outcomes, NMR status and pharmacotherapy 
moderated by the type of behavioural treatment received? 
Lastly, a higher order interaction was included in the sensitivity analysis to determine whether 
the putative effect of NMR status on pharmacotherapy effectiveness is dependent on the type 
of behavioural support provided. This was considered, at least in part, as we had previously 
observed self-selection of group support by NMR, where normal metabolizers were less likely 
to use group support.(30) Behavioural support choice moderated the impact of the NMR status 
by pharmacotherapy choice relationship on the 52-week (Wald Χ2=6.33, p=0.012) but not 4-
week follow-up abstinence rates. As can be seen in Figure 2, the relative benefit of varenicline 
over NRT at 52-week follow-up was greater in slow metabolisers receiving group rather than 
individual support (adjusted RR for interaction 11.3, 95%CI 1.76-71.7; p=0.011), whereas this 
was not the case for normal metabolisers (adjusted RR for interaction 0.71, 95%CI 0.25-2.02; 
p=0.515). These results were not materially altered when including additional covariate-
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exposure interactions for two established determinants for smoking cessation, nicotine 
dependence and social grade (61). 
 
Discussion 
This study set out to evaluate whether NMR status moderates the impact of NRT relative to 
varenicline on smoking cessation rates in a general population sample of treatment seeking 
smokers. Contrary to previous clinical work,(41) we did not observe a benefit of varenicline 
over NRT for normal metabolisers as compared with slow metabolisers. We also did not find 
any differences in abstinence rates between normal and slow metabolisers when controlling for 
other known confounders. In agreement with previous work,(42, 61, 62) greater abstinence 
rates were associated with lower dependence and living together with a partner and, to a lesser 
degree, with social grade as well as treatment with varenicline rather than NRT. Short-term 
abstinence only was also associated with older age, determination to quit and group rather than 
individual support as has been previously shown.(54, 63) 
Several reasons may account for the failure to replicate clinical trial findings in this real-world 
study. First, this may be due to differences in the socio-demographic composition of the type 
of participants included in clinical trials and population studies. Clinical trials often exclude 
smokers with comorbidities such as mental health issues and may attract more proactive 
participants, motivated by financial remuneration. The NMR-based clinical trial also excluded 
individuals taking drugs which were known inhibitors of CYP2A6, which could transiently (or 
longer) convert a normal metabolizer to a slow metabolizer.(41) By contrast, our study 
passively recruited all smokers attending stop smoking services, who were not reimbursed for 
participation. Second, and relatedly, given ethnic variation in NMR,(27) our results may reflect 
genuine differences in UK vs. North American smokers, where the current trial was 95% white, 
This article is protected by copyright. All rights reserved. 
which was substantially lower (55% white) in the North American trial.(41) Third, while 
clinical trials have high internal validity assessing efficacy of treatments with high fidelity and 
good implementation, they lack the external validity of population studies which assess 
treatment effectiveness outside a controlled environment, with suboptimal implementation. 
Fourth, clinical trials will seek to maximise follow-up response to obtain an accurate estimate 
of the treatment effect whereas follow-up rates in population studies such as ours tend to be 
lower, leading to potential underestimates of treatment effects in the context of intention-to-
treat analysis. Fifth, compliance was not assessed, and it is difficult to compare drug effects if 
compliance differs. The NRT arms differed substantially, with the majority of NRT users being 
dual users while the previous clinical trial used only transdermal patch. It is possible that dual 
NRT is as useful for normal metabolizers as varenicline. Lastly, and importantly, whereas in 
clinical trials participants are randomly allocated to treatment, smokers in our study self-
selected their treatment and normal metabolizers were less likely to use group support (see 
limitations below). Although we did control for a range of covariates, the difference in this 
study and the previous clinical trial may therefore in part reflect confounding due to factors not 
accounted for. 
While we did not detect the predicted interaction of NMR status with pharmacotherapy type 
on smoking cessation outcomes, we did observe an association of NMR status with 
pharmacotherapy effectiveness as a function of the behavioural support provided. Specifically, 
the effectiveness of varenicline over NRT was markedly more pronounced in the context of 
group rather than individual behavioural support but only for slow and not normal metabolisers. 
It should be acknowledged that this finding needs to be interpreted with caution, given small 
numbers. Individual support is more commonly accessed via community practitioners (e.g. 
General Practitioners, pharmacists) who provide shorter and fewer counselling sessions 
whereas group support is almost exclusively accessed via specialist stop smoking clinics which 
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provide more intensive, longer treatment, often over six to eight face-to-face sessions.(46) 
Given that varenicline has a worse side-effect profile for slow rather than normal 
metabolisers,(41) slow metabolisers may discontinue varenicline earlier in the context of 
individual support, with less intensive support and limited advice on medication adherence. By 
contrast, being provided with more extensive advice on medication side effects and the 
importance of adherence in the context of group support, slow metabolisers may be more likely 
to continue treatment with varenicline, resulting in superior outcomes. This would be less of 
an issue for normal metabolisers who experience fewer side-effects. 
This study has a number of limitations. As previously mentioned, participants self-selected 
their treatment and thus findings may be the result of an artefact due to confounding. Although 
we controlled for a range of potentially important covariates, not all putative factors (including 
medication adherence) were measured and some variables were only assessed with a single 
item. In particular as previously reported, normal metabolisers were less likely to choose group 
behavioural support,(30) which appears to affect pharmacotherapy outcome in this analysis. 
While the longitudinal design allowed us to investigate temporal effects, it did result in high 
levels of attrition and relatively small numbers of smokers who had quit by the end of the study, 
limiting our power to detect more complex effects. Moreover, even though we used a 
prospective design, this does not allow us to make causal claims. Finally, while the initial 
sample collected was largely representative of smokers seeking treatment in the UK, there were 
some marked demographic and treatment differences between those who had complete data 
and were included in the analysis and those who were excluded. Findings may therefore not 
generalise beyond the current sample. 
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Conclusions 
Our study did not replicate clinical trial data, suggesting that NMR status of treatment-seeking 
smokers does not substantially contribute to differential pharmacotherapy effectiveness in Stop 
Smoking Services, when both pharmacotherapy and behavioural support are self-selected. 
While there may be a number of reasons for this, one potential explanation for this finding is 
the distinctly different effect that varying levels of behavioural support may have on treatment 
with NRT and varenicline for slow vs normal metabolisers. If correct and corroborated by 
further studies, this interpretation would have clear implications for treatment delivery to slow 
and normal metabolisers: the benefits of varenicline over NRT previously identified may only 
become apparent for slow metabolisers if sufficient behavioural support is provided. 
Altogether, our results suggest that NMR status may not have a large effect on real-world self-
selected treatment outcomes and that the impact of NMR may be context-dependent. While 
this suggests one potential reason for the apparent discordance in the literature, further 
clarification of the role of the rate of nicotine metabolism, choice of group counselling and 
their interaction with treatment effect is required. Specifically, it will be important to 
understand 1) whether dual NRT behaves the same as transdermal NRT alone with respect to 
NMR predicting outcomes in the context of clinical trials and 2) the impact of the type of 
counselling (and associated treatment adherence) on NMR status by pharmacotherapy effects 
in the context of real-world settings where treatment choice is based on NMR status which is 
prescriber-selected rather than self-selected.  
This article is protected by copyright. All rights reserved. 
Declarations 
Ethics approval and consent to participate 
The study received ethical approval from the South East Scotland Research Ethics Committee 
(11/AL/0256) and from University of Toronto. All participants included in this analysis 
consented to take part and research complied with the ethical principles on human research, 
as per the Declaration of Helsinki. 
Consent for publication 
Not applicable. 
Availability of data and material 
Questionnaires and anonymised datasets generated and/or analysed during the current study 
are available from the corresponding author on reasonable request. 
Funding 
The ELONS study was funded by the NIHR HTA program (09/161/01) and by the Global 
Research Awards for Nicotine Dependence (GRAND) unrestricted research grant program 
supported by Pfizer. This work received additional support from a grant by the former UK 
Centre for Tobacco Control Studies (UKCTCS), funded under the auspices of the UK Clinical 
Research Collaboration (RES-590-28-0004). Lion Shahab, Ann McNeill and Linda Bauld are 
members of the UK Centre for Tobacco and Alcohol Studies (UKCTAS), funded under the 
auspices of the above UK Clinical Research Collaboration (MR/K023195/1). We acknowledge 
the support of CIHR (FDN-154294), a Canada Research Chair in Pharmacogenomics (RFT), 
the Centre for Addiction and Mental Health and the CAMH Foundation, the Canada 
Foundation for Innovation (grant numbers 20289 and 16014), and the Ontario Ministry of 
Research and Innovation.  
This article is protected by copyright. All rights reserved. 
Author contributions statement 
LB and LS conceived the original idea for this study. LB, AM, RFT and LS obtained funding. 
LB and LS managed the day-to-day running of the study. RFT undertook the sample analysis 
and LS undertook the data analyses and wrote the initial draft with further input from all 
authors. LS is guarantor for this article. LB, AM, RFT and LS read, reviewed and approved the 
final version. All researchers listed as authors are independent from the funders and all final 
decisions about the research were taken without constraint by the investigators. LS had full 
access to all the data in the study and had ﬁnal responsibility for the decision to submit for 
publication. 
Acknowledgements 
The rigorous efforts made by the ELONS researchers to recruit services onto the study, the 
extensive planning involved in conducting the study and the collation of the generous amount 
of data is greatly appreciated. Please see Dobbie et al (2015) for the full list of researchers 
involved in the original study. The authors would also like to thank Chloe Lam, Jayde Dix and 
Eleanor Bennett for assisting with the labelling and sorting of the saliva samples at University 
College London.   
This article is protected by copyright. All rights reserved. 
References 
1. STEAD L. F., KOILPILLAI P., FANSHAWE T. R., LANCASTER T. Combined 
pharmacotherapy and behavioural interventions for smoking cessation, Cochrane 
Database of Systematic Reviews 2016: 3: CD008286. 
2. HUGHES J. R., STEAD L. F., HARTMANN-BOYCE J., CAHILL K., LANCASTER T. 
Antidepressants for smoking cessation, Cochrane Database SystRev 2014: 1: 
CD000031. 
3. STEAD L. F., BUITRAGO D., PRECIADO N., SANCHEZ G., HARTMANN-BOYCE J., 
LANCASTER T. Physician advice for smoking cessation, Cochrane Database Syst Rev 
2013: 5: CD000165. 
4. STEAD L. F., PERERA R., BULLEN C., MANT D., HARTMANN-BOYCE J., CAHILL K. et al. 
Nicotine replacement therapy for smoking cessation, Cochrane Database SystRev 
2012: 11: CD000146. 
5. CAHILL K., LINDSON-HAWLEY N., THOMAS K. H., FANSHAWE T. R., LANCASTER T. 
Nicotine receptor partial agonists for smoking cessation, Cochrane Database of 
Systematic Reviews 2016: CD006103. 
6. STEAD L. F., LANCASTER T. Group behaviour therapy programmes for smoking 
cessation, Cochrane Database Syst Rev 2005: CD001007. 
7. LANCASTER T., STEAD L. F. Individual behavioural counselling for smoking cessation, 
Cochrane Database Syst Rev 2017: 3: CD001292. 
8. LI M. D., CHENG R., MA J. Z., SWAN G. E. A meta-analysis of estimated genetic and 
environmental effects on smoking behavior in male and female adult twins, Addiction 
2003: 98: 23-31. 
9. RAY R., TYNDALE R. F., LERMAN C. Nicotine dependence pharmacogenetics: role of 
genetic variation in nicotine-metabolizing enzymes, J Neurogenet 2009: 23: 252-261. 
10. BOUGH K. J., LERMAN C., ROSE J. E., MCCLERNON F. J., KENNY P. J., TYNDALE R. F. et 
al. Biomarkers for smoking cessation, Clin Pharmacol Ther 2013: 93: 526-538. 
11. MAMOUN M., BERGEN A. W., SHIEH J., WIGGINS A., BRODY A. L. Biomarkers of 
Response to Smoking Cessation Pharmacotherapies: Progress to Date, CNS Drugs 
2015: 29: 359-369. 
This article is protected by copyright. All rights reserved. 
12. BROCK A. J., TAKEDA A., BRENNAN C., WALTON R. T. Treatment for tobacco 
dependence: a potential application for stratified medicine?, Per Med 2011: 8: 571-579. 
13. DEMPSEY D., TUTKA P., JACOB P., III, ALLEN F., SCHOEDEL K., TYNDALE R. F. et al. 
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity, 
ClinPharmacolTher 2004: 76: 64-72. 
14. NAKAJIMA M., YAMAMOTO T., NUNOYA K., YOKOI T., NAGASHIMA K., INOUE K. et al. 
Role of human cytochrome P4502A6 in C-oxidation of nicotine, Drug Metabolism and 
Disposition 1996: 24: 1212-1217. 
15. MESSINA E. S., TYNDALE R. F., SELLERS E. M. A major role for CYP2A6 in nicotine C-
oxidation by human liver microsomes, J PharmacolExpTher 1997: 282: 1608-1614. 
16. THORGEIRSSON T. E., GUDBJARTSSON D. F., SURAKKA I., VINK J. M., AMIN N., GELLER 
F. et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking 
behavior, Nat Genet 2010: 42: 448-453. 
17. WASSENAAR C. A., DONG Q., WEI Q., AMOS C. I., SPITZ M. R., TYNDALE R. F. 
Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and 
smoking behaviors and lung cancer risk, J NatlCancer Inst 2011: 103: 1342-1346. 
18. BENOWITZ N. L., HUKKANEN J., JACOB P., 3RD. Nicotine chemistry, metabolism, 
kinetics and biomarkers, Handb Exp Pharmacol 2009: 29-60. 
19. CHENOWETH M. J., NOYALEN M., HAWK L. W., SCHNOLL R. A., GEORGE T. P., 
CINCIRIPINI P. et al. Known and Novel Sources of Variability in the Nicotine Metabolite 
Ratio in a Large Sample of Treatment-Seeking Smokers, Cancer EpidemiolBiomarkers 
Prev 2014. 
20. ALLENBY C. E., BOYLAN K. A., LERMAN C., FALCONE M. Precision Medicine for 
Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio, 
J Neuroimmune Pharmacol 2016: 11: 471-483. 
21. LEA R. A., DICKSON S., BENOWITZ N. L. Within-subject variation of the salivary 
3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme 
activity in large-scale surveys of nicotine metabolic rate, J AnalToxicol 2006: 30: 386-
389. 
22. MOONEY M. E., LI Z. Z., MURPHY S. E., PENTEL P. R., LE C., HATSUKAMI D. K. Stability 
of the nicotine metabolite ratio in ad libitum and reducing smokers, Cancer 
Epidemiology Biomarkers & Prevention 2008: 17: 1396-1400. 
This article is protected by copyright. All rights reserved. 
23. HAMILTON D. A., MAHONEY M. C., NOVALEN M., CHENOWETH M. J., HEITJAN D. F., 
LERMAN C. et al. Test-retest reliability and stability of the nicotine metabolite ratio 
among treatment-seeking smokers, Nicotine & Tobacco Research 2015: 17: 1505-
1509. 
24. BENOWITZ N. L., SWAN G. E., JACOB P., III, LESSOV-SCHLAGGAR C. N., TYNDALE R. F. 
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine, 
ClinPharmacolTher 2006: 80: 457-467. 
25. ST HELEN G., NOVALEN M., HEITJAN D. F., DEMPSEY D., JACOB P., 3RD, AZIZIYEH A. et 
al. Reproducibility of the nicotine metabolite ratio in cigarette smokers, Cancer 
Epidemiol Biomarkers Prev 2012: 21: 1105-1114. 
26. FOGLI S., SABA A., DEL RE M., PISTELLI F., AQUILINI F., ZUCCHI R. et al. Application 
of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic 
profile of smokers in the real-life setting, J Pharm Biomed Anal 2016: 131: 208-213. 
27. RUBINSTEIN M. L., SHIFFMAN S., RAIT M. A., BENOWITZ N. L. Race, gender, and 
nicotine metabolism in adolescent smokers, Nicotine Tob Res 2013: 15: 1311-1315. 
28. JOHNSTONE E., BENOWITZ N., CARGILL A., JACOB R., HINKS L., DAY I. et al. 
Determinants of the rate of nicotine metabolism and effects on smoking behavior, Clin 
Pharmacol Ther 2006: 80: 319-330. 
29. LOUKOLA A., BUCHWALD J., GUPTA R., PALVIAINEN T., HALLFORS J., TIKKANEN E. et 
al. A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism, PLoS 
Genet 2015: 11: e1005498. 
30. SHAHAB L., MORTIMER E., BAULD L., MCGOWAN J. A., MCNEILL A., TYNDALE R. F. 
Characterising the nicotine metabolite ratio and its association with treatment choice: 
A cross sectional analysis of Stop Smoking Services in England, Sci Rep 2017: 7: 
17613. 
31. WEST O., HAJEK P., MCROBBIE H. Systematic review of the relationship between the 3-
hydroxycotinine/cotinine ratio and cigarette dependence, Psychopharmacology (Berl) 
2011: 218: 313-322. 
32. STRASSER A. A., BENOWITZ N. L., PINTO A. G., TANG K. Z., HECHT S. S., CARMELLA S. 
G. et al. Nicotine metabolite ratio predicts smoking topography and carcinogen 
biomarker level, Cancer EpidemiolBiomarkers Prev 2011: 20: 234-238. 
This article is protected by copyright. All rights reserved. 
33. SCHNOLL R. A., PATTERSON F., WILEYTO E. P., TYNDALE R. F., BENOWITZ N., LERMAN 
C. Nicotine metabolic rate predicts successful smoking cessation with transdermal 
nicotine: a validation study, PharmacolBiochemBehav 2009: 92: 6-11. 
34. LERMAN C., TYNDALE R., PATTERSON F., WILEYTO E. P., SHIELDS P. G., PINTO A. et al. 
Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking 
cessation, ClinPharmacolTher 2006: 79: 600-608. 
35. PATTERSON F., SCHNOLL R. A., WILEYTO E. P., PINTO A., EPSTEIN L. H., SHIELDS P. G. 
et al. Toward personalized therapy for smoking cessation: a randomized placebo-
controlled trial of bupropion, ClinPharmacolTher 2008: 84: 320-325. 
36. CHENOWETH M. J., SCHNOLL R. A., NOVALEN M., HAWK L. W., JR., GEORGE T. P., 
CINCIRIPINI P. M. et al. The Nicotine Metabolite Ratio is Associated With Early 
Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine 
Metabolite Ratio, Nicotine Tob Res 2016: 18: 491-495. 
37. CHEN L. S., BLOOM A. J., BAKER T. B., SMITH S. S., PIPER M. E., MARTINEZ M. et al. 
Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene 
(CYP2A6), Addiction 2014: 109: 128-137. 
38. FIX B. V., O'CONNOR R. J., BENOWITZ N., HECKMAN B. W., CUMMINGS K. M., FONG G. 
T. et al. Nicotine metabolite ratio (NMR) prospectively predicts smoking relapse: 
Longitudinal findings from ITC Surveys in five countries, Nicotine Tob Res 2017. 
39. VAZ L. R., COLEMAN T., COOPER S., AVEYARD P., LEONARDI-BEE J., TEAM S. T. The 
Nicotine Metabolite Ratio in Pregnancy Measured by trans-3'-Hydroxycotinine to 
Cotinine Ratio: Characteristics and Relationship With Smoking Cessation, Nicotine 
Tob Res 2015: 17: 1318-1323. 
40. SCHUIT E., PANAGIOTOU O. A., MUNAFO M. R., BENNETT D. A., BERGEN A. W., DAVID 
S. P. Pharmacotherapy for smoking cessation: effects by subgroup defined by 
genetically informed biomarkers, Cochrane Database Syst Rev 2017: 9: CD011823. 
41. LERMAN C., SCHNOLL R. A., HAWK L. W., JR., CINCIRIPINI P., GEORGE T. P., WILEYTO 
E. P. et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of 
response to nicotine patch or varenicline for smoking cessation: a randomised, double-
blind placebo-controlled trial, Lancet Respir Med 2015: 3: 131-138. 
42. ANTHENELLI R. M., BENOWITZ N. L., WEST R., ST AUBIN L., MCRAE T., LAWRENCE D. 
et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch 
in smokers with and without psychiatric disorders (EAGLES): a double-blind, 
randomised, placebo-controlled clinical trial, Lancet 2016: 387: 2507-2520. 
This article is protected by copyright. All rights reserved. 
43. DAVID S. P. Commentary on Chen et al. (2014): another step on the road to clinical 
utility of pharmacogenetics for smoking cessation?, Addiction 2014: 109: 138-139. 
44. SHERMAN R. E., ANDERSON S. A., DAL PAN G. J., GRAY G. W., GROSS T., HUNTER N. 
L. et al. Real-World Evidence - What Is It and What Can It Tell Us?, N Engl J Med 
2016: 375: 2293-2297. 
45. KOTZ D., BROWN J., WEST R. 'Real-world' effectiveness of smoking cessation 
treatments: a population study, Addiction 2014: 109: 491-499. 
46. DOBBIE F., HISCOCK R., LEONARDI-BEE J., MURRAY S., SHAHAB L., AVEYARD P. et al. 
Evaluating Long-term Outcomes of NHS Stop Smoking Services (ELONS): a 
prospective cohort study, Health Technol Assess 2015: 19: 1-156. 
47. SHAHAB L., DOBBIE F., HISCOCK R., MCNEILL A., BAULD L. Prevalence and Impact of 
Long-term Use of Nicotine Replacement Therapy in UK Stop-Smoking Services: 
Findings From the ELONS Study, Nicotine Tob Res 2018: 20: 81-88. 
48. WEST R., HAJEK P., STEAD L., STAPLETON J. Outcome criteria in smoking cessation 
trials: proposal for a common standard, Addiction 2005: 100: 299-303. 
49. BERNERT J. T., JACOB P., III, HOLIDAY D. B., BENOWITZ N. L., SOSNOFF C. S., DOIG M. 
V. et al. Interlaboratory comparability of serum cotinine measurements at smoker and 
nonsmoker concentration levels: a round-robin study, Nicotine Tob Res 2009: 11: 
1458-1466. 
50. TANNER J. A., NOVALEN M., JATLOW P., HUESTIS M. A., MURPHY S. E., KAPRIO J. et al. 
Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different 
analytical methods and laboratories: implications for clinical implementation, Cancer 
Epidemiol Biomarkers Prev 2015: 24: 1239-1246. 
51. CHENOWETH M. J., WARE J. J., ZHU A. Z. X., COLE C. B., COX L. S., NOLLEN N. et al. 
Genome-wide association study of a nicotine metabolism biomarker in African 
American smokers: impact of chromosome 19 genetic influences, Addiction 2017. 
52. CHENOWETH M. J., SYLVESTRE M. P., CONTRERAS G., NOVALEN M., O'LOUGHLIN J., 
TYNDALE R. F. Variation in CYP2A6 and tobacco dependence throughout adolescence 
and in young adult smokers, Drug Alcohol Depend 2016: 158: 139-146. 
53. ROSE D., PEVALIN D. J., O'REILLY K. The National Statistics Socio-economic 
Classification: origins, development and use  Basingstoke: Palgrave MacMillan; 2005. 
This article is protected by copyright. All rights reserved. 
54. BAULD L., BELL K., MCCULLOUGH L., RICHARDSON L., GREAVES L. The effectiveness 
of NHS smoking cessation services: a systematic review, J Public Health (Oxf) 2010: 
32: 71-82. 
55. HEATHERTON T. F., KOZLOWSKI L. T., FRECKER R. C., RICKERT W., ROBINSON J. 
Measuring the heaviness of smoking: using self-reported time to the first cigarette of 
the day and number of cigarettes smoked per day, Br J Addict 1989: 84: 791-799. 
56. SCHNOLL R. A., GOREN A., ANNUNZIATA K., SUAYA J. A. The prevalence, predictors 
and associated health outcomes of high nicotine dependence using three measures 
among US smokers, Addiction 2013: 108: 1989-2000. 
57. WORLD HEALTH ORGANISATION. Well-being measures in primary health care: the 
DepCare project, Copenhagen, Denmark: WHO Regional OFfice for Europe; 1998. 
58. TOPP C. W., OSTERGAARD S. D., SONDERGAARD S., BECH P. The WHO-5 Well-Being 
Index: a systematic review of the literature, Psychother Psychosom 2015: 84: 167-176. 
59. HOSMER D. W., LEMESHOW S. Applied Logistic Regression: New York: Wiley; 1989. 
60. DIENES Z. Using Bayes to get the most out of non-significant results, Front Psychol 
2014: 5: 781. 
61. VANGELI E., STAPLETON J., SMIT E. S., BORLAND R., WEST R. Predictors of attempts to 
stop smoking and their success in adult general population samples: a systematic 
review, Addiction 2011: 106: 2110-2121. 
62. FERGUSON J., BAULD L., CHESTERMAN J., JUDGE K. The English smoking treatment 
services: one-year outcomes, Addiction 2005: 100 Suppl 2: 59-69. 
63. JUDGE K., BAULD L., CHESTERMAN J., FERGUSON J. The English smoking treatment 
services: short-term outcomes, Addiction 2005: 100 Suppl 2: 46-58. 
This article is protected by copyright. All rights reserved. 
Table 1: Sample characteristics by data availability 
All participants 
Total Sample 
(N=3,044) 
 
Analytic 
Sample 
(N=1,556) 
Excluded 
Sample 
(N=1,488) 
P 
Mean (SD) age 42.5 (14.1)  41.8 (14.1) 43.2 (14.1) 0.004 
% (N) Female 55.9 (1,701)  52.3 (814) 59.6 (887) <0.001 
% (N) Higher SES (ABC1) 23.4 (712)  23.9 (372) 22.8 (340) 0.494 
% (N) White 96.0 (2,922)  94.9 (1,477) 97.1 (1,445) 0.002 
% (N) Married/Cohabiting 47.0 (1,431)  46.7 (727) 47.3 (704) 0.771 
% (N) Poor physical health 56.2 (1,711)  56.0 (871) 56.5 (840) 0.798 
% (N) Poor wellbeing 44.7 (1,318)  43.1 (671) 46.5 (647)* 0.064 
% (N) Higher dependence score 
(HSI≥ 4) 
49.4 (1,489)  47.8 (743) 51.1 (746)† 0.068 
% (N) Past year quit attempt 41.5 (1,237)  40.9 (637) 42.0 (600)‡ 0.552 
% (N) Determination to quit                  § <0.001 
 Not at all 8.8 (261)  8.4 (131) 9.1 (130)  
 Very determined 39.5 (1,176)  43.0 (669) 35.6 (507)  
 Extremely determined 51.8 (1,542)  48.6 (756) 55.2 (786)  
% (N) Behavioural support                     ‖ <0.001 
 Individual support 78.6 (2,385)  75.7 (1,178) 81.7 (1,207)  
 Group support 21.4 (648)  24.3 (378) 18.3 (270)  
% (N) Pharmacological support     <0.001 
 Single NRT¶  17.7 (540)  17.2 (268) 18.3 (272)  
 Combination NRT** 30.6 (933)  36.9 (574) 24.1 (359)  
 Varenicline 43.0 (1,308)  45.9 (714) 39.9 (594)  
 Bupropion 0.9 (27)  - 1.8 (27)  
 Varenicline and NRT 4.2 (129)  - 8.7 (129)  
 Other combination 0.2 (5)  - 0.3 (5)  
 None 3.4 (102)  - 6.9 (102)  
% (N) SSS Region     <0.001 
 North 50.3 (1,532)  44.9 (699) 56.0 (833)  
This article is protected by copyright. All rights reserved. 
 Midlands 38.3 (1,166)  41.6 (647) 34.9 (519)  
 South 11.4 (346)  13.5 (210) 9.1 (136)  
Participants with valid saliva sample (N=1,826)  (N=1,556) (N=270) 
 
% (N) Slow metabolisers 28.5 (520)  29.0 (451) 25.6 (69) 0.273 
SES = socioeconomic status; HSI = Heaviness of Smoking Index; NRT =Nicotine replacement therapy; SSS = Stop smoking services; *98 cases 
missing; †29 cases missing; ‡61 cases missing; §65 cases missing; ‖11 cases missing; ¶Single NRT products used were patches (N=361; 66.9%), 
inhalator (N=64; 11.9%), lozenges (N=64; 11.9%), gum (N=26; 4.8%), nasal/mouth spray (N=23; 4.3%) and minitabs (N=2; 0.4%); 
**Combination NRT most commonly involved patch together with inhalator (N=289; 31.0%), lozenge (N=182; 19.5%), nasal/mouth spray 
(N=153; 16.4%) or gum (N=85; 9.1%) and around 16% (N=178) used more than two NRT products concurrently 
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Table 2: Associations between sample characteristics and smoking cessation outcomes at 4-week and 12-month follow-up 
Adj. RR = adjusted risk ratio (adjusted for all variables shown); CI = confidence interval; NMR = nicotine metabolite ratio; HSI = Heaviness of 
Smoking Index; SES = socioeconomic status; NRT = nicotine replacement therapy; SSS = Stop smoking services; WHO – World Health 
Organisation; ref. = reference category 
 Verified continuous abstinence 
(N=1,556) 
4-week follow-up 12-month follow-up 
Adj. RR (95%CI)  P Adj. RR (95%CI)  P Adj. RR (95%CI) P Adj. RR (95%CI) P 
NMR x Pharmacotherapy (indicator: slow 
NMR and NRT) 
0.88 (0.55-1.40) 0.586 - - 1.15 (0.51-2.58) 0.741 - - 
Normal NMR (ref. slow NMR) 1.08 (0.78-1.49) 0.664 1.01 (0.80-1.28) 0.940 0.85 (0.46-1.56) 0.591 0.91 (0.61-1.37) 0.657 
Varenicline (ref. NRT) 1.69 (1.14-2.51) 0.009 1.54 (1.24-1.91) <0.001 1.32 (0.67-2.58) 0.420 1.45 (0.99-2.12) 0.056 
Group support (ref. individual support) 1.54 (1.17-2.02) 0.002 1.54 (1.17-2.03) 0.002 1.29 (0.82-2.04) 0.270 1.29 (0.81-2.04) 0.281 
Age 1.50 (1.33-1.70) <0.001 1.50 (1.33-1.70) <0.001 1.15 (0.95-1.40) 0.143 1.16 (0.95-1.40) 0.144 
Female (ref. male) 1.16 (0.93-1.43) 0.188 1.16 (0.93-1.43) 0.188 0.82 (0.56-1.20) 0.297 0.82 (0.56-1.20) 0.298 
Higher SES/ABC1 (ref. C2DE) 1.43 (1.11-1.83) 0.005 1.43 (1.11-1.83) 0.005 1.43 (0.96-2.14) 0.081 1.43 (0.95-2.14) 0.083 
White ethnicity (ref. other ethnicity)  0.98 (0.60-1.61) 0.938 0.99 (0.60-1.62) 0.963 1.19 (0.44-3.21) 0.737 1.18 (0.44-3.16) 0.746 
Married/Cohabiting (ref. single) 1.35 (1.09-1.67) 0.006 1.35 (1.09-1.67) 0.006 1.64 (1.11-2.41) 0.012 1.64 (1.11-2.41) 0.012 
Poor physical health (ref. good physical 
health) 
0.90 (0.71-1.13) 0.352 0.90 (0.71-1.13) 0.358 1.03 (0.68-1.56) 0.880 1.03 (0.68-1.56) 0.884 
Poor wellbeing/WHO score ≤50% (ref. 
WHO score >50%) 
1.08 (0.87-1.35) 0.470 1.08 (0.87-1.35) 0.479 1.29 (0.88-1.89) 0.196 1.29 (0.88-1.90) 0.191 
Higher dependence/HSI≥ 4 (ref. HSI <4) 0.75 (0.60-0.93) 0.008 0.74 (0.60-0.92) 0.007 0.55 (0.38-0.81) 0.002 0.56 (0.38-0.81) 0.002 
Determination to quit 
 Very (ref. not determined) 
 Extremely (ref. not determined) 
 
1.73 (1.16-2.60) 
2.19 (1.47-3.28) 
 
0.008 
<0.001 
 
1.73 (1.16-2.59) 
2.19 (1.47-3.27) 
 
0.008 
<0.001 
 
0.80 (0.42-1.54) 
0.86 (0.45-1.64) 
 
0.512 
0.641 
 
0.81 (0.42-1.54) 
0.86 (0.45-1.64) 
 
0.514 
0.646 
Past year quit attempt (ref. no attempt) 0.90 (0.73-1.12) 0.345 0.90 (0.73-1.12) 0.354 0.75 (0.51-1.12) 0.156 0.75 (0.51-1.11) 0.153 
SSS Region 
 North (ref. South) 
 Midlands (ref. South) 
 
1.50 (1.06-2.11) 
1.65 (1.17-2.33) 
 
0.021 
0.005 
 
1.51 (1.07-2.13) 
1.66 (1.17-2.34) 
 
0.019 
0.004 
 
1.60 (0.82-3.14) 
1.85 (0.94-3.64) 
 
0.172 
0.077 
 
1.59 (0.81-3.13) 
1.84 (0.93-3.63) 
 
0.179 
0.079 
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Figure 1: Raw continuous abstinence rates by pharmacotherapy type and NMR status 
(N=1,556) 
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Figure 2: Adjusted continuous 12-month verified abstinence rates based on estimated marginal 
means by pharmacotherapy and behavioural support type and NMR status (N=1,556) 
 
